xCellSense® quantifies synergy and antagonism for your asset against standard-of-care backbones, directly in primary patient samples, with ML-integrated scoring and regimen ranking.
The combination value varies among patients and is often inaccurately predicted by cell lines. We evaluate your compound both alone and in combination with standard-of-care (SoC) therapeutics and other standard agents using the same primary samples, and then measure the actual performance of these combinations.
Synergy matrices
Quantitative scoring across multiple frameworks (Bliss, Loewe, ZIP, HSA) with detection of antagonism.
Combination dose-response
Full dose-response across the combination grid, per sample.
Responder Fraction
Estimated proportion of samples showing combination benefit.
ML-integrated ranking
Machine-learning-supported synergy scoring that ranks regimens and identifies patient subgroups most likely to benefit.
Key Deliverables
A scientist — not a sales desk — will scope a tailored study and return a design and timeline.
